Cytokine induced killer cell(Italian Sarcoma Group)(Cytokine induced killer cell(Italian Sarcoma Group))

概要

基本信息

药物类型

细胞因子诱导的杀伤细胞疗法

别名

Autologous CIK (Italian Sarcoma Group)

靶点-

作用机制

CIK细胞替代物(细胞因子诱导的杀伤细胞替代物)

治疗领域

肿瘤

在研适应症-

非在研适应症

肉瘤

原研机构

Italian Sarcoma Group

在研机构-

非在研机构

Italian Sarcoma GroupAzienda Ospedaliera Ospedale Infantile Regina Margherita Sant Anna

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Cytokine induced killer cell(Italian Sarcoma Group) 相关的临床试验

NCT04802070 / Completed临床1期IIT

A Phase I Study of Adoptive Immunotherapy With Cytokine-Induced Killer Cells in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.

Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer (CIK).
In the first part of the study Patient's' peripheral blood will be collected and CIK cell expansion and storage will occur at the Regina Margherita Children's Hospital Cell Factory.
In the second part of the study the Maximum Tolerated Dose (MTD) will be determined in order to find the Recommended Dose for Phase II (RP2D)

开始日期2021-01-11

申办/合作机构

Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant Anna

NCT03782363 / Withdrawn临床1期IIT

A Phase I Study of Adoptive Immunotherapy With Cytokine-Induced Killer Cells in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.

Monocentric, phase I study for advanced sarcoma with adoptive immunotherapy with Cytokine-Induced Killer (CIK).
In the first part of the study Patient's' peripheral blood will be collected and CIK cell expansion and storage will occur at the Regina Margherita Children's Hospital Cell Factory.
In the second part of the study the Maximum Tolerated Dose (MTD) will be determined in order to find the Recommended Dose for Phase II (RP2D)

开始日期2020-12-18

申办/合作机构

Italian Sarcoma Group

[+1]

ChiCTR1900022309 / Suspended早期临床1期IIT

A Randomized Controlled Study for Autologous DC-CIK Sequential Combined With Entecavir in the Treatment of Chronic Hepatitis B Virus

开始日期2019-09-01

申办/合作机构-

100 项与 Cytokine induced killer cell(Italian Sarcoma Group) 相关的临床结果

登录后查看更多信息

100 项与 Cytokine induced killer cell(Italian Sarcoma Group) 相关的转化医学

登录后查看更多信息

100 项与 Cytokine induced killer cell(Italian Sarcoma Group) 相关的专利（医药）

登录后查看更多信息

8

项与 Cytokine induced killer cell(Italian Sarcoma Group) 相关的文献（医药）

2021-09-08·Journal of Healthcare Engineering4区 · 医学

Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies

4区 · 医学

ArticleOA

作者: Zhao, Yi-Yi ; Wang, Run-Qing ; Meng, Ming-Yao ; Zhong, Yi-Ming ; Yang, Yang ; Hou, Zong-Liu ; Yang, Li-Rong ; Li, Lin

Cytokine-induced killer (CIK) cells have been proved to be an effective method of tumor immunotherapy in numerous preclinical and clinical studies. In our previous study, a new method was developed to prime and propagate CIK cells by the combination of IL-2 and IL-15, and this kind of CIK cells had enhanced antitumor effect on lung cancer. For renal cell carcinoma (RCC), immunotherapy plays an important role because of the poor efficacy of radiotherapy and chemotherapy. In this study, we further evaluated the antitumor effects of these enhanced CIK cells against RCC. Enhanced CIK cells were generated by IL-2 combined with IL-15 and identified by flow cytometry. HEK-293 and ACHN cell lines were used to verify the efficiency of CIK cells in vitro, and then the ACHN tumor xenograft model was also employed for in vivo study. In addition, the secreted cytokines including IFN-γ, granzyme B, TNF-α, and perforin, as well as the local microstructure were also studied. Subsequently, 20 patients with RCC were enrolled into our study, and 11 patients were randomly divided into the autologous CIK treatment group for clinical research. The results showed that enhanced CIK cells exert better antitumor effects in RCC in vitro (

p < 0.01

in HEK-293 and

p < 0.05

in ACHN）and in vivo (

p < 0.05

). Patients benefit overall survival from enhanced CIK therapy in our clinical study. Our present preclinical and clinical studies for the first time elucidated that these enhanced CIK cells would be used as an effective adjuvant therapy in the treatment of RCC.

2019-06-01·Zhongguo shi yan xue ye xue za zhi

[Efficacy of Autologous DC-CIK Cells Combined with Other Immune Cells in the Treatment of Hematological Malignancies -Retrospective Study].

Article

作者: Li, Xi-Ran ; Zhang, Mei ; Liu, Hai-Bo ; Ma, Tian-Tian ; Liu, Hua-Sheng ; Shi, Jing

题目自体DC-CIK细胞联合其它免疫细胞治疗血液系统肿瘤的回顾性研究.目的探讨自体DC-CIK细胞联合其它免疫细胞用于治疗血液系统肿瘤患者的安全性、临床疗效及预后.方法回顾性研究西安交通大学第一附属医院自2014年9月至2016年4月期间接受细胞免疫治疗的血液系统肿瘤患者50例临床资料（共计完成细胞治疗115例次）。根据选择的治疗方案将患者分为双细胞治疗组(DC-CIK治疗)和多细胞治疗组(DC-CIK联合其它免疫细胞)；根据治疗疗程分为单疗程组(完成次数＜3次)和多疗程组(完成次数≥3次)。分析比较患者治疗前后T淋巴细胞亚群、血常规指标、KPS评分变化及总生存期.结果按2种方法分组，2组患者治疗前的一般情况包括入组数量、性别、年龄、各T淋巴细胞亚群、血常规指标、KPS评分等方面的比较，差异无统计学意义，说明2组具有可比性。按治疗方案分组，双细胞组治疗后CD4⁺/CD8⁺比值较治疗前降低，血常规指标中Hb、Plt水平较治疗前降低，治疗前后相比，差异均具有统计学意义(P＜0.05)。多细胞组患者治疗后CD3⁺CD4⁺比例较治疗前降低，差异具有统计学意义(P＜0.05)。双细胞组患者3年生存率61.3%，总生存期32.4个月，多细胞组3年生存率69.8%，总生存期39.6个月，2组对比差异无统计学意义(P>0.05)。按治疗疗程分组，单疗程组患者治疗后CD3⁺比例较治疗前升高，血Hb水平较治疗前下降，差异均具有统计学意义(P＜0.05)；多疗程组患者治疗后CD3⁺CD4⁺比例较前下降，血Plt较前下降，KPS评分较治疗前升高，差异均具有统计学意义(P＜0.05)。 2组患者活存情况对比显示，单疗程组3年生存率52%，总生存期28.7个月；多疗程组3年生存率76.4%，总生存期40.9个月，两组对比差异具有统计学意义(P＜0.05).结论自体DC-CIK细胞联合其它免疫细胞治疗血液系统肿瘤可改变患者的免疫功能，提高杀伤肿瘤的作用，且多疗程的细胞治疗可提高患者的生活质量，延长生存期，值得临床推广.

2019-04-01·Pathology & Oncology Research4区 · 医学

Combined Treatment with Autologous CIK Cells, Radiotherapy and Chemotherapy in Advanced Cervical Cancer

4区 · 医学

Article

作者: Liu, Zong-Lan ; Tian, Yong-Wei ; Meng, Dan-Dan ; Xu, Zhi-Qiao ; Gao, Ling ; Li, Ning ; Xu, Yue ; Shen, Wen-Jie

To investigate the clinical efficacy of autologous cytokine induced killer (CIK) cells transfusion combined with radiochemotherapy in the treatment of advanced cervical cancer. A total of 89 hospitalized patients with advanced cervical cancer were admitted and divided into the treatment group (44 cases, autologous CIK cells transfusion combined with radiochemotherapy) and the control group (45 cases, radiochemotherapy) by a randomized non-blind method. Comparisons of therapeutic efficacies, immune functions, life qualities and survival rates were analyzed between the two groups. The short-term therapeutic efficacy of the treatment group was significantly higher than that of the control group. There was no significant difference in 1, 2 and 3 year survival rates between the two groups. Compared with pre-treatment, levels of CD3⁺, CD4⁺/CD8⁺ in peripheral blood were increased in the CIK group, which were reduced in the control group. In the CIK group,only the feeling was depressed on the 25th day post-treatment (T25) compared with the day before treatment (B1). However in the control group, the function of body, role, social and holistic health was obvious disordered on day T25 compared with day B1. On day T25, there were significant differences in function of body, social and holistic health between two groups. Autologous CIK cells transfusion combined with radiochemotherapy shows better short-term efficacy than radiochemotherapy alone in the treatment of advanced cervical cancer, which obviously improves immune function and life quality of patients with low side effects.

100 项与 Cytokine induced killer cell(Italian Sarcoma Group) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肉瘤	临床1期	意大利	Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant Anna	2020-12-18
肉瘤	临床1期	意大利	Italian Sarcoma Group	2020-12-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


QUILT-3.039/3.060/3.070/3.080 (ASCO2020)	N/A	胰腺癌	12	Chemoradiation + cytokine-induced NK and T cell activation + checkpoint inhibition + allogeneic haNK cells	(鹹鑰憲簾繭顧衊構窪觸) = 50% 膚窪鑰襯醖範獵襯鬱衊 (網簾廠築鹽衊遞淵築積 ) 更多	积极	2020-05-25
ASCO2012	N/A	肺癌	-	Autologous cytokine-induced killer (Autologous CIK and DC)	(餘積夢願網簾製餘窪餘) = 簾鏇憲積選遞壓願蓋蓋網艱範顧餘選繭衊鹹膚 (餘憲窪艱獵願艱繭鏇鑰 )	积极	2012-05-20